Genomics guiding personalized first-line immunotherapy response in lung and bladder tumors.

doi:10.1186/s12967-025-06323-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genomics guiding personalized first-line immunotherapy response in lung and bladder tumors.

Journal of translational medicine - 5 Apr 2025

Brea-Iglesias Jenifer, Gallardo-Gómez María, Oitabén Ana, Lázaro-Quintela Martin E, León Luis, Alves Joao M, Pino-González Manuel, Juaneda-Magdalena Laura, García-Benito Carme, Abdulkader Ihab, Muinelo Laura, Paramio Jesús M, Martínez-Fernández Mónica

Abstract excerpt

BACKGROUND: Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment, particularly in advanced non-small cell lung cancer (NSCLC) and muscle-invasive bladder cancer (MIBC). However, identifying reliable predictive biomarkers for ICI response remains a significant challenge. In this study, we analyzed real-world cohorts of advanced NSCLC and MIBC patients treated with ICI as first-line therapy....

Read the complete abstract on PubMed

Topics

Humans
Urinary Bladder Neoplasms
Lung Neoplasms
Immunotherapy
Genomics

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Precision Medicine

Mutation

Female

Male

Carcinoma, Non-Small-Cell Lung

Treatment Outcome

Aged

Middle Aged

Haplotypes

Biomarkers, Tumor

Immune Checkpoint Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 40188131
DOI: 10.1186/s12967-025-06323-7
PMCID: PMC11972471

Genes

FGFR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomics guiding personalized first-line immunotherapy response in lung and bladder tumors.PMID 40188131Read ↗

Genomic Insights Guiding Personalized First-Line Immunotherapy Response in Lung and Bladder TumorsSemantic proximity Read ↗

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read ↗

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung CancerSemantic proximity Read ↗

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read ↗

Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients.Semantic proximity Read ↗

Recurrent somatic mutations as predictors of immunotherapy response.Semantic proximity Read ↗

Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.Semantic proximity Read ↗

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy.Semantic proximity Read ↗

Pan-cancer analysis of tumor mutational burden and homologous recombination DNA damage repair by targeted next-generation sequencingSemantic proximity Read ↗

Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression.Semantic proximity Read ↗

Clinicogenomic Predictors of First-line Immune Checkpoint Inhibitor Outcomes in Non-Small Cell Lung Cancer: A Nationwide CCAT Cohort From Japan.Semantic proximity Read ↗

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.